Orforglipron — Oral non-peptide GLP-1 receptor agonist (small molecule)

Orforglipron is clinically significant because it offers true oral convenience — no injections, no dietary restrictions, and no permeation enhancer required. Phase 2 data (NEJM, 2023): 36mg dose achieved 14.7% weight loss from baseline in non-diabetic obese individuals over 36 weeks — the highest weight loss ever seen for an oral weight management drug. In T2DM populations, HbA1c reductions were comparable to injectable GLP-1 agonists. The main differentiator from Rybelsus (oral semaglutide) is accessibility: Rybelsus requires 30-minute fasting, taken with only 4oz water, and bioavailability is only ~1% even under optimal conditions. Orforglipron's small-molecule design achieves ~3-5% oral bioavailability with no dietary restrictions, potentially expanding GLP-1 therapy to populations who cannot or will not inject.